Using zebrafish models of leukemia to streamline drug screening and discovery
- Deveau, A.P., Bentley, V.L., Berman, J.N.
- Experimental hematology 45: 1-9 (Review)
- Registered Authors
- Bentley, Victoria, Berman, Jason, Deveau, Adam
- MeSH Terms
- Animals, Genetically Modified
- Antineoplastic Agents/pharmacology*
- Antineoplastic Agents/therapeutic use
- Disease Models, Animal
- Drug Discovery*
- Drug Evaluation, Preclinical*
- High-Throughput Screening Assays*
- Leukemia/drug therapy
- Xenograft Model Antitumor Assays
- 27720937 Full text @ Exp. Hematol.
Deveau, A.P., Bentley, V.L., Berman, J.N. (2017) Using zebrafish models of leukemia to streamline drug screening and discovery. Experimental hematology. 45:1-9.
Current treatment strategies for acute leukemias largely rely on nonspecific cytotoxic drugs that result in high therapy-related morbidity and mortality. Cost effective, pertinent animal models are needed to link in vitro studies with the development of new therapeutic agents in clinical trials on a high-throughput scale. However, targeted therapies have had limited success moving from bench-to-clinic, often due to unexpected off-target effects. The zebrafish has emerged as a reliable in vivo tool for modeling human leukemia. Zebrafish genetic and xenograft models of acute leukemia provide an unprecedented opportunity to conduct rapid phenotype-based screens. This prospect allows for the identification of relevant therapies, while simultaneously evaluating drug toxicity, circumventing the limitations of target-centric approaches.
Genes / Markers
Mutation and Transgenics
Human Disease / Model Data
Sequence Targeting Reagents
Engineered Foreign Genes
Errata and Notes